...
首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Effect of vitamin K2 on bone mineral density and serum cathepsin K in female osteoporosis patients
【24h】

Effect of vitamin K2 on bone mineral density and serum cathepsin K in female osteoporosis patients

机译:维生素K2对女性骨质疏松症患者骨矿物质密度和血清组织蛋白酶K的影响

获取原文
           

摘要

Purpose: To investigate the influence of vitamin K 2 on bone mineral density, bone metabolism and serum tissue protease K (cathepsin K) in female patients with osteoporosis. Method: A total of 210 osteoporosis patients in Affiliated Hospital of Nanjing University of Chinese Medicine who met the inclusion criteria were selected from January 2017 to January 2018. The patients were randomly divided into vitamin K 2 group, strontium renate group and blank control group (70 patients/group). Strontium ranelate group was orally given 2 g of strontium ranelate daily, while vitamin K 2 group received 15 mg of Gulikang capsule 3 times a day. Bone mineral density (BMD) and serum osteocalcin (BGP), β-collagen degradation product (β-crosslaps), type I procollagen amino terminal pro-peptide (PINP), cathepsin K (cathe K) and TRAP were measured prior to drug treatment, and six months after surgery, using standard procedures. Results: Relative to the blank control, hip and lumbar spine density of vitamin K 2 and strontium ranelate groups increased to varying degrees. Strontium ranelate group had significantly higher bone mineral density (BMD) than any other groups (p 0.05), and also had the lowest osteoclast activity (β-crosslaps and TRAP) and the highest osteogenic activity (BGP and PINP). On the other hand, osteoclast and osteogenic activities increased significantly (p 0.05) in the vitamin K 2 group. Conclusion: Appropriate vitamin K 2 treatment improves BMD in the hip and waist of women with osteoporosis by promoting osteogenic activity, and by reducing osteoclast activity and cathepsin K ex pression.
机译:目的:探讨维生素K 2对骨质疏松症女性患者骨矿物质密度,骨代谢和血清组织蛋白酶K(组织蛋白酶K)的影响。方法:选择2017年1月至2018年1月南京中医药大学附属医院收治的210例骨质疏松患者。将患者随机分为维生素K 2组,锶锶组和空白对照组( 70名患者/组)。雷奈酸锶组每天口服雷奈酸锶2g,维生素K 2组每天3次,口服古力康胶囊15mg。在药物治疗之前,先测量骨矿物质密度(BMD)和血清骨钙素(BGP),β胶原降解产物(β-crosslaps),I型前胶原氨基末端前肽(PINP),组织蛋白酶K(cathe K)和TRAP。 ,以及术后六个月,使用标准程序。结果:相对于空白对照组,维生素K 2和雷奈酸锶组的臀部和腰椎密度有所不同。雷奈酸锶组的骨矿物质密度(BMD)高于其他任何组(p <0.05),破骨细胞活性最低(β-crosslaps和TRAP),成骨活性最高(BGP和PINP)。另一方面,维生素K 2组的破骨细胞和成骨活性显着增加(p <0.05)。结论:适当的维生素K 2治疗可通过促进成骨活性,降低破骨细胞活性和组织蛋白酶K的表达来改善骨质疏松症妇女臀部和腰部的BMD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号